The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)
F Nguyen-Khac, A Bidet, A Daudignon… - Leukemia, 2022 - nature.com
Karyotype complexity has major prognostic value in many malignancies. There is no
consensus on the definition of a complex karyotype, and the prognostic impact of karyotype …
consensus on the definition of a complex karyotype, and the prognostic impact of karyotype …
[HTML][HTML] Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment
Plasma cell leukemia is a rare and aggressive plasma cell dyscrasia associated with dismal
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del (1p32) remains a strong prognostic factor
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …
Experts' consensus on the definition and management of high risk multiple myeloma
C Marcon, V Simeon, P Deias, G Facchin… - Frontiers in …, 2023 - frontiersin.org
High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
[HTML][HTML] Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma
Multiple myeloma (MM) patients with high-risk cytogenetic abnormalities have inferior
survival outcomes and are underrepresented in clinical trials. There is scarce data on MM …
survival outcomes and are underrepresented in clinical trials. There is scarce data on MM …
Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma
MN Sadhu, D Sivanandhan, C Gajendran… - Bioorganic & medicinal …, 2021 - Elsevier
Abstract Lysine specific demethylase 1 (LSD1) and HDAC6 are epigenetic proteins
associated with several diseases, including cancer and combined inhibition of these …
associated with several diseases, including cancer and combined inhibition of these …
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Introduction: Multiple myeloma (MM) remains an incurable disease with a median overall
survival of approximately 5 years. Gain or amplification of 1q21 (1q21+) occurs in around …
survival of approximately 5 years. Gain or amplification of 1q21 (1q21+) occurs in around …
Aberrant BUB1 overexpression promotes mitotic segregation errors and chromosomal instability in multiple myeloma
Y Fujibayashi, R Isa, D Nishiyama, N Sakamoto-Inada… - Cancers, 2020 - mdpi.com
Chromosome instability (CIN), the hallmarks of cancer, reflects ongoing chromosomal
changes caused by chromosome segregation errors and results in whole chromosomal or …
changes caused by chromosome segregation errors and results in whole chromosomal or …
[HTML][HTML] Chromosomal defects in multiple myeloma
SE Clarke, KA Fuller, WN Erber - Blood Reviews, 2024 - Elsevier
Multiple myeloma is a plasma cell neoplasm driven by primary (eg hyperdiploidy; IGH
translocations) and secondary (eg 1q21 gains/amplifications; del (17p); MYC translocations) …
translocations) and secondary (eg 1q21 gains/amplifications; del (17p); MYC translocations) …
Genetic predictors of mortality in patients with multiple myeloma
Multiple myeloma (MM) is a heterogeneous disease featured by clonal plasma cell
proliferation and genomic instability. The advent of next-generation sequencing allowed …
proliferation and genomic instability. The advent of next-generation sequencing allowed …